Home > Insider Trading > Filing (0001562180-20-003587)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434418	Constellation Pharmaceuticals Inc	CNST	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1745787	Jigar Raythatha	C/O Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200 Cambridge MA 02142	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-05-11	26	$5.51	14,987	No	4	M	Direct
Common Stock	Disposition	2020-05-11	26	$50.00	14,961	No	4	S	Direct
Common Stock	Acquisiton	2020-05-12	9,209	$5.51	24,170	No	4	M	Direct
Common Stock	Disposition	2020-05-12	9,209	$50.17	14,961	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-05-11	26	$0.00	26	$5.51
Common Stock	Stock Option (Right to Buy)	Disposition	2020-05-12	9,209	$0.00	9,209	$5.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
433,149		2027-07-10	No	4	M	Direct
423,940		2027-07-10	No	4	M	Direct

Footnotes

These trades were made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $50.00 to $50.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on July 11, 2017. The shares underlying the option are scheduled to vest as to 25% of the shares underlying the option on March 20, 2018, with the remainder vesting in equal quarterly installments through March 20, 2021.